BACKGROUND AND PURPOSE: This review discusses recent research on the genetic, molecular, cellular, and developmental mechanisms underlying the etiology of vascular malformations of the brain (VMBs), including cerebral cavernous malformation, sporadic brain arteriovenous malformation, and the arteriovenous malformations of hereditary hemorrhagic telangiectasia. Summary of Review- The identification of gene mutations and genetic risk factors associated with cerebral cavernous malformation, hereditary hemorrhagic telangiectasia, and sporadic arteriovenous malformation has enabled the development of animal models for these diseases and provided new insights into their etiology. All of the genes associated with VMBs to date have known or plausible roles in angiogenesis and vascular remodeling. Recent work suggests that the angiogenic process most severely disrupted by VMB gene mutation is that of vascular stabilization, the process whereby vascular endothelial cells form capillary tubes, strengthen their intercellular junctions, and recruit smooth muscle cells to the vessel wall. In addition, there is now good evidence that in some cases, cerebral cavernous malformation lesion formation involves a genetic 2-hit mechanism in which a germline mutation in one copy of a cerebral cavernous malformation gene is followed by a somatic mutation in the other copy. There is also increasing evidence that environmental second hits can produce lesions when there is a mutation to a single allele of a VMB gene. CONCLUSIONS: Recent findings begin to explain how mutations in VMB genes render vessels vulnerable to rupture when challenged with other inauspicious genetic or environmental factors and have suggested candidate therapeutics. Understanding of the cellular mechanisms of VMB formation and progression in humans has lagged behind that in animal models. New knowledge of lesion biology will spur new translational work. Several well-established clinical and genetic database efforts are already in place, and further progress will be facilitated by collaborative expansion and standardization of these.
BACKGROUND AND PURPOSE: This review discusses recent research on the genetic, molecular, cellular, and developmental mechanisms underlying the etiology of vascular malformations of the brain (VMBs), including cerebral cavernous malformation, sporadic brain arteriovenous malformation, and the arteriovenous malformations of hereditary hemorrhagic telangiectasia. Summary of Review- The identification of gene mutations and genetic risk factors associated with cerebral cavernous malformation, hereditary hemorrhagic telangiectasia, and sporadic arteriovenous malformation has enabled the development of animal models for these diseases and provided new insights into their etiology. All of the genes associated with VMBs to date have known or plausible roles in angiogenesis and vascular remodeling. Recent work suggests that the angiogenic process most severely disrupted by VMB gene mutation is that of vascular stabilization, the process whereby vascular endothelial cells form capillary tubes, strengthen their intercellular junctions, and recruit smooth muscle cells to the vessel wall. In addition, there is now good evidence that in some cases, cerebral cavernous malformation lesion formation involves a genetic 2-hit mechanism in which a germline mutation in one copy of a cerebral cavernous malformation gene is followed by a somatic mutation in the other copy. There is also increasing evidence that environmental second hits can produce lesions when there is a mutation to a single allele of a VMB gene. CONCLUSIONS: Recent findings begin to explain how mutations in VMB genes render vessels vulnerable to rupture when challenged with other inauspicious genetic or environmental factors and have suggested candidate therapeutics. Understanding of the cellular mechanisms of VMB formation and progression in humans has lagged behind that in animal models. New knowledge of lesion biology will spur new translational work. Several well-established clinical and genetic database efforts are already in place, and further progress will be facilitated by collaborative expansion and standardization of these.
Authors: Robert Shenkar; Palamadai N Venkatasubramanian; Alice M Wyrwicz; Jin-cheng Zhao; Changbin Shi; Amy Akers; Douglas A Marchuk; Issam A Awad Journal: Neurosurgery Date: 2008-10 Impact factor: 4.654
Authors: Janneke van Beijnum; Caroline E Lovelock; Charlotte Cordonnier; Peter M Rothwell; Catharina J M Klijn; Rustam Al-Shahi Salman Journal: Brain Date: 2008-11-28 Impact factor: 13.501
Authors: Helen Kim; Pirro G Hysi; Ludmila Pawlikowska; Annie Poon; Esteban González Burchard; Jonathan G Zaroff; Stephen Sidney; Nerissa U Ko; Achal S Achrol; Michael T Lawton; Charles E McCulloch; Pui-Yan Kwok; William L Young Journal: Cerebrovasc Dis Date: 2008-12-18 Impact factor: 2.762
Authors: Amy L Akers; Eric Johnson; Gary K Steinberg; Joseph M Zabramski; Douglas A Marchuk Journal: Hum Mol Genet Date: 2008-12-16 Impact factor: 6.150
Authors: Kevin J Whitehead; Aubrey C Chan; Sutip Navankasattusas; Wonshill Koh; Nyall R London; Jing Ling; Anne H Mayo; Stavros G Drakos; Christopher A Jones; Weiquan Zhu; Douglas A Marchuk; George E Davis; Dean Y Li Journal: Nat Med Date: 2009-01-18 Impact factor: 53.440
Authors: Benjamin Kleaveland; Xiangjian Zheng; Jian J Liu; Yannick Blum; Jennifer J Tung; Zhiying Zou; Shawn M Sweeney; Mei Chen; Lili Guo; Min-min Lu; Diane Zhou; Jan Kitajewski; Markus Affolter; Mark H Ginsberg; Mark L Kahn Journal: Nat Med Date: 2009-01-18 Impact factor: 53.440
Authors: Edit Dósa; Suchita Tuladhar; Leslie L Muldoon; Bronwyn E Hamilton; William D Rooney; Edward A Neuwelt Journal: Stroke Date: 2011-04-14 Impact factor: 7.914
Authors: Jose Gutierrez; Sally Sultan; Ahmet Bagci; Tatjana Rundek; Noam Alperin; Mitchell S V Elkind; Ralph L Sacco; Clinton B Wright Journal: Cerebrovasc Dis Date: 2013-11-23 Impact factor: 2.762